Elbrus Capital Fund III

2021

Acquisition of a stake in Breffi

Elbrus Capital Fund III has acquired a large minority stake in, a Breffi the Russian omnikanalny marketing pharmaceutical brand company. This Elbrus Capital was announced Zdrav.Expert on December 29, 2021. The transaction amount amounted to 750 million rubles. Most of the funds will be used to develop the company, scale the current business and create new digital products in the field. health care More. here

Investing in the developer of AI solutions for the Rubbles business

In mid-December 2021, it became known about the investment of $6 million in Rubbles. The developer of AI solutions for business, founded by Russians, received funds from Elbrus Capital Fund III and FinSight Ventures. More details here.

Investing in international translation service TransferGo

In mid-October 2021, TransferGo received $50 million during the Series C financing round, as a result of which the total amount of funds raised by the service amounted to $77 million. The funding round was led by the Russian fund Elbrus Capital Fund III and Black River Ventures, which was joined by the new investor Unlimint and existing investors, including Hard Yaka, VEF, SmartHub and Milano Investments. More details here.

Create a $600 million fund to invest in IT, finance and pharmaceuticals

On January 21, 2021, it became known about the creation of Elbrus Capital of the third fund with a target volume of $600 million. Funds from Elbrus Capital Fund III will be directed to projects working in such areas as digital technology and the Internet, consumer goods and services, the financial sector and pharmaceuticals.

At the same time, Dmitry Kryukov, a senior partner of Elbrus Capital funds, said in a conversation with Kommersant that the main emphasis would be on digital companies, since, according to him, Russia has a very developed, dynamic digital economy, many unique world-class companies and products.

Elbrus Capital has created a $600 million fund to invest in IT, finance and pharmaceuticals

Kryukov noted that funds usually invest in already held, profitable companies, with a proven business model. Controlling or large minority shares are bought. Sometimes there can be experiments with smaller investments.

After the acquisition, active work is carried out to increase the cost of companies, for example, a motivational option program for employees is immediately introduced - "management and shareholders should be in the same boat." In addition, companies invested by funds, as a rule, actively take part in M&A transactions to increase their market share, develop new business lines, etc., a senior partner of Elbrus Capital funds told the publication.

By January 21, 2021, Elbrus Capital raised $260 million in the Elbrus Capital Fund III from international institutional investors, including sovereign wealth funds of the Middle East, the European Development Institute and others. The first investment deals are scheduled for the first quarter. MVision Private Equity Advisers acted as a global consultant on raising funds for the fund. Clifford Chance acted as a legal consultant. Elbrus Capital Fund III plans to fully form within 2021-2022 years.^[1]

Notes